[go: up one dir, main page]

EE200100187A - Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga - Google Patents

Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga

Info

Publication number
EE200100187A
EE200100187A EEP200100187A EEP200100187A EE200100187A EE 200100187 A EE200100187 A EE 200100187A EE P200100187 A EEP200100187 A EE P200100187A EE P200100187 A EEP200100187 A EE P200100187A EE 200100187 A EE200100187 A EE 200100187A
Authority
EE
Estonia
Prior art keywords
acetyldinaline
capecitabine
gemcitabine
cisplatin
combination
Prior art date
Application number
EEP200100187A
Other languages
English (en)
Estonian (et)
Inventor
Richard Grove William
Daniel Klohs Wayne
Lynn Merriman Ronald
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200100187A publication Critical patent/EE200100187A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EEP200100187A 1998-09-25 1999-07-08 Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga EE200100187A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25
PCT/US1999/015386 WO2000018393A1 (fr) 1998-09-25 1999-07-08 Chimiotherapie contre le cancer, dans laquelle de l'acetyldinaline combinee a de la gemcitabine, de la capecitabine ou du cisplatine sont utilises

Publications (1)

Publication Number Publication Date
EE200100187A true EE200100187A (et) 2002-08-15

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100187A EE200100187A (et) 1998-09-25 1999-07-08 Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga

Country Status (34)

Country Link
US (3) US6469058B1 (fr)
EP (1) EP1115391B1 (fr)
JP (1) JP2002525320A (fr)
KR (1) KR20010075348A (fr)
CN (1) CN1319009A (fr)
AP (1) AP2001002109A0 (fr)
AT (1) ATE225655T1 (fr)
AU (1) AU762079B2 (fr)
BG (1) BG105470A (fr)
BR (1) BR9913952A (fr)
CA (1) CA2342981A1 (fr)
CZ (1) CZ2001905A3 (fr)
DE (1) DE69903458T2 (fr)
DK (1) DK1115391T3 (fr)
EA (1) EA200100369A1 (fr)
EE (1) EE200100187A (fr)
ES (1) ES2185378T3 (fr)
GE (1) GEP20043199B (fr)
HK (1) HK1040190A1 (fr)
HR (1) HRP20010225B1 (fr)
HU (1) HUP0103640A3 (fr)
ID (1) ID30046A (fr)
IL (1) IL141951A0 (fr)
IS (1) IS5888A (fr)
NO (1) NO20011493L (fr)
NZ (1) NZ510504A (fr)
OA (1) OA11659A (fr)
PL (1) PL348673A1 (fr)
PT (1) PT1115391E (fr)
SK (1) SK3602001A3 (fr)
TR (1) TR200100859T2 (fr)
WO (1) WO2000018393A1 (fr)
YU (1) YU22401A (fr)
ZA (1) ZA200102233B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1115391T3 (da) * 1998-09-25 2003-02-10 Warner Lambert Co Kemoterapi af cancer med acetyldinalin i kombination med gemcitabin, capecitabin eller cisplatin
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (fr) 2002-04-23 2003-10-23 Celator Technologies Inc. Composes synergiques
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
BR0308250A (pt) * 2002-03-04 2005-01-11 Aton Pharma Inc Métodos de indução de diferenciação terminal
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
CA2506085A1 (fr) * 2002-11-15 2004-06-03 Ronald Lynn Merriman Polychimiotherapie anticancereuse a base d'inhibiteur mek et de capecitabine
RU2240117C1 (ru) * 2003-04-01 2004-11-20 Алтайский государственный медицинский университет Способ лечения больных с местнораспространенными формами плоскоклеточного рака с локализацией в области слизистой оболочки полости рта и ротового отдела глотки
EP1643971A2 (fr) * 2003-05-22 2006-04-12 Neopharm, Inc. Formulations liposomales combinees
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
CA2616299A1 (fr) 2005-07-22 2007-02-01 Tomotherapy Incorporated Procede de placement de contraintes sur une carte de deformations et systeme pour la mise en oeuvre du procede
WO2007014091A2 (fr) 2005-07-22 2007-02-01 Tomotherapy Incorporated Systeme et procede de generation de structures de contour mettant en oeuvre un histogramme de volume de dosage
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
CA2616309A1 (fr) 2005-07-22 2007-02-01 Tomotherapy Incorporated Procede et systeme permettant de prevoir l'administration de doses
EP1906827A4 (fr) 2005-07-22 2009-10-21 Tomotherapy Inc Systeme et methode pour evaluer une dose administree par un systeme de radiotherapie
AU2006272742A1 (en) 2005-07-22 2007-02-01 Tomotherapy Incorporated System and method of delivering radiation therapy to a moving region of interest
JP2009502255A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 治療プランのデリバリにおける品質保証基準を評価するための方法およびシステム
CN101268476A (zh) 2005-07-22 2008-09-17 断层放疗公司 用于处理与放射疗法治疗计划相关的数据的方法和系统
US7643661B2 (en) 2005-07-22 2010-01-05 Tomo Therapy Incorporated Method and system for evaluating delivered dose
EP1907065B1 (fr) 2005-07-22 2012-11-07 TomoTherapy, Inc. Methode et systeme pour adapter un programme de traitement de radiotherapie en fonction d'un modele biologique
CN101267768A (zh) 2005-07-22 2008-09-17 断层放疗公司 对接受放射疗法的患者的呼吸时相进行检测的系统和方法
WO2007014090A2 (fr) 2005-07-23 2007-02-01 Tomotherapy Incorporated Procede d'imagerie et d'administration d'une radiotherapie dans lequel sont utilises un portique et un support mobile a mouvements coordonnes
RU2009111605A (ru) 2006-08-31 2010-10-10 Спектрум Фармасьютикалз, Инк. (Us) Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина
KR101560339B1 (ko) * 2008-01-28 2015-10-14 나노캐리어 가부시키가이샤 의약 조성물 또는 조합제
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
WO2010118006A1 (fr) 2009-04-06 2010-10-14 Eisai Inc. Dérivés de (2 ' -désoxy-ribofuranosyl) -1,3,4, 7-tétrahydro- (1,3) iazépine-2-0ne pour le traitement du cancer
WO2012003413A1 (fr) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Nouvelles formes solides de tacédinaline
US8729130B2 (en) 2011-07-01 2014-05-20 The Broad Institute, Inc. Methods of using novel solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711007A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine destiné à être utilisé dans le traitement ou la prévention du cancer du sein et de la prostate primitif et métastatique
EP2711008A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine destiné à être utilisé dans le traitement ou la prévention du cancer du sein primitif et métastatique
EP2711009A1 (fr) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Composés destinés à être utilisés dans le traitement ou la prévention du cancer primitif et métastatique du sein et de la prostate
EP2962309B1 (fr) 2013-02-26 2022-02-16 Accuray, Inc. Collimateur multilame actionné par voie électromagnétique
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
WO2020028392A1 (fr) 2018-07-30 2020-02-06 Duke University Analogues de niclosamide et leur utilisation thérapeutique

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
WO1998047500A1 (fr) * 1997-04-24 1998-10-29 Warner-Lambert Company Utilisation de l'acetyldinaline pour fabriquer un medicament destine au traitement du nephrocarcinome
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
DK1115391T3 (da) * 1998-09-25 2003-02-10 Warner Lambert Co Kemoterapi af cancer med acetyldinalin i kombination med gemcitabin, capecitabin eller cisplatin

Also Published As

Publication number Publication date
DK1115391T3 (da) 2003-02-10
CA2342981A1 (fr) 2000-04-06
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
US6469058B1 (en) 2002-10-22
NO20011493D0 (no) 2001-03-23
BR9913952A (pt) 2001-06-12
DE69903458D1 (de) 2002-11-14
HUP0103640A2 (en) 2002-06-29
HRP20010225A2 (en) 2002-04-30
YU22401A (sh) 2004-03-12
SK3602001A3 (en) 2002-07-02
DE69903458T2 (de) 2003-07-10
ID30046A (id) 2001-11-01
JP2002525320A (ja) 2002-08-13
AU5092199A (en) 2000-04-17
EP1115391A1 (fr) 2001-07-18
PL348673A1 (en) 2002-06-03
WO2000018393A1 (fr) 2000-04-06
EP1115391B1 (fr) 2002-10-09
US20030086965A1 (en) 2003-05-08
ZA200102233B (en) 2002-06-18
BG105470A (en) 2001-12-29
NZ510504A (en) 2003-09-26
ES2185378T3 (es) 2003-04-16
HK1040190A1 (zh) 2002-05-31
GEP20043199B (en) 2004-03-25
ATE225655T1 (de) 2002-10-15
TR200100859T2 (tr) 2001-08-21
US20030170300A1 (en) 2003-09-11
CN1319009A (zh) 2001-10-24
HRP20010225B1 (en) 2004-10-31
EA200100369A1 (ru) 2001-10-22
KR20010075348A (ko) 2001-08-09
AU762079B2 (en) 2003-06-19
OA11659A (en) 2004-12-08
PT1115391E (pt) 2003-02-28
CZ2001905A3 (cs) 2001-08-15
NO20011493L (no) 2001-05-23
AP2001002109A0 (en) 2001-03-31
IS5888A (is) 2001-03-14

Similar Documents

Publication Publication Date Title
EE200100187A (et) Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga
EE200000577A (et) Elektronpääsmete või nendega seotud täiustused
PT1114031E (pt) 4-carboxiamino-1,2,3,4-tetradhiroquinolinas substituidas em posicao 2
NO20006520L (no) Adenosinderivater
BR9912040B1 (pt) vÁlvula em profundidade, e acabamento de poÇo.
EE9600156A (et) Hüpertooniavastaste, kardioprotektiivsete, isheemia- ja lipolüüsivastaste omadustega ühendid
NO20013099L (no) Kombinasjonskjemoterapi
ZA992255B (en) Antitumor synergetic composition.
DE69901338D1 (de) Mikroprozessor mit mehreren registersätzen, die den gleichen logischen raum besitzen
DK1070402T3 (da) Forbedringer angående sikkerhed i datakonferencer
NO20020394D0 (no) Parenteral cisplatinemulsjon
SI1115391T1 (en) Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
TR199900635A3 (tr) Pozitif kontrollü tüylendirme silindirleri içeren tüylendirme makinesi.
FR2779658B1 (fr) Planche de glisse
DE59904544D1 (de) Waffe, insbesondere panzerabwehrwaffe
IT245830Y1 (it) Autoveicolo con sedili anteriori girevoli.
ES1039380Y (es) Pendiente de cierre delantero.
KR980000233U (ko) 주머니를 구비한 장갑
ES1040517Y (es) Sembradora de semillas en bandejas.
BR8101034Y1 (pt) disposição introduzida em luminária de embutir.
ES1041848Y (es) Perfil frontal para cerraduras.
ES1040895Y (es) Maletin-pupitre escolar.
SK2354U (sk) Dvere s požiarnou odolnosťou 30 minút, bezpečnostné-nepriestrelné
BR8202541Y1 (pt) aperfeiçoamento introduzido em bolsão.
ES1042631Y (es) Banco continuo ondulado-circular, con respaldo ergonomico.